Clinical performance of an antibody-free assay for plasma A[beta]42/A[beta]40 to detect early alterations of Alzheimer's disease in individuals with subjective cognitive decline
Background Accessible and cost-effective diagnostic tools are urgently needed to accurately quantify blood biomarkers to support early diagnosis of Alzheimer's disease (AD). In this study, we investigated the ability of plasma amyloid-beta (A[beta])42/A[beta]40 ratio measured by an antibody-fre...
Gespeichert in:
Veröffentlicht in: | Alzheimer's research & therapy 2023-01, Vol.15 (1) |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Schreiben Sie den ersten Kommentar!